hapabapa/iStock Editorial via Getty Images
Novo Nordisk (NVO) (OTCPK:NONOF) announced on Sunday that its popular weight loss drug Wegovy resulted in more than a 50% decrease in serious heart issues … [+62 chars]
Novo's Wegovy beats Lilly’s Zepbound in real-world study for heart diseases - Seeking Alpha
Novo Nordisk (NVO) stock in focus as its obesity drug Wegovy outperforms Eli Lilly's (LLY) rival Zepbound in reducing serious heart issues by over 50%. Read more here.
By:Dulan Lokuwithana
Source:Seeking Alpha
Published:
Related News
My Friend Has Been Sucked Into One of the Darkest Groups in the Parenting Community. I Can’t Stand By Her. - Slate
This sucks.
Slate Magazine•Logan Sachon
My Rude, Nosy Mother-in-Law Just “Had” to Walk in On Us Having Sex. Our Sex Life Will Never Be the Same. - Slate
My husband hasn't been able to perform since.
Slate Magazine•Rich Juzwiak
Outbreak of deadly virus with no cure and 'epidemic potential' reported in India as officials issue severe warning - LADbible
Health officials are battling to contain an outbreak of Nipah virus - which has no vaccine or cure - after five people were infected in West Bengal.
LADbible•Olivia Burke